On Oct. 26, AstraZeneca
- Revenues fell short of analyst estimates by 2.5%, while EPS exceeded analyst estimates by 3.8%.
- Sales increased by 12.6% to $6.516 billion, because of strong performance from the cardiovascular and neuroscience segments.
- Net income increased by 29.4% to $1.592 billion, because of increased revenues and improved margins.
- EPS grew by 32.9%, because of an increase in net profit and a decrease in diluted shares.
- FCF increased because of higher net income, resulting in stronger cash generated from operations.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Avg. Est. |
Q3 2006 |
Q3 2005 |
Change |
|
|---|---|---|---|---|
|
Sales |
$6,686 |
$6,516 |
$5,789 |
12.6% |
|
Net Profit |
-- |
$1,592 |
$1,230 |
29.4% |
|
EPS |
$0.97 |
$1.01 |
$0.76 |
32.9% |
|
Diluted Shares |
-- |
1,569 |
1,613 |
(2.7%) |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q3 2006 |
Q3 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
79.45% |
78.49% |
0.96 |
|
Operating Margin |
32.32% |
29.28% |
3.04 |
|
Net Margin |
24.43% |
21.25% |
3.18 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$5,756 |
$4,400 |
30.8% |
|
Accounts Rec. |
$5,404 |
$4,776 |
13.2% |
|
Inventory |
$2,209 |
$2,493 |
(11.4%) |
|
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$5,780 |
$5,404 |
7.0% |
|
Long-Term Debt |
N/A |
N/A |
N/A |
Learn the ways of the balance sheet.
Cash Flow Highlights
|
YTD 2006 |
YTD 2005 |
Change |
|
|---|---|---|---|
|
Cash From Ops. |
$5,533 |
$4,814 |
14.9% |
|
Capital Expenditures |
$565 |
$586 |
(3.6%) |
|
Free Cash Flow |
$4,968 |
$4,228 |
17.5% |
Find out why Fools always follow the money.
Related Companies:
-
Wyeth
(NYSE:WYE) -
Abbott Laboratories
(NYSE:ABT) -
Merck & Co.
(NYSE:MRK)
Related Foolishness:
- Market Rejects AstraZeneca's Remedy
- AstraZeneca Needs a Rest
- AstraZeneca's Path to Avoid Pain
- What to Make of Bristol-Myers
To find out what more than 11,500 fellow investors think about AstraZeneca - and add your voice to the mix - check out CAPS , the Fool's new community-intelligence stock-rating tool. Merck is a former Motley Fool Income Investor selection.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
